$NXL News

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

Nexalin Technology Secures Key Neurostimulation Legislative Provision In Appropriations Bill Passed By U.S. House Of Representatives

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

Nexalin Technology Acquires Digital Health Platform PONM From GreenLight Ventures; Financial Terms Not Disclosed

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Nexalin Announces Publication Of Peer-Reviewed Study In Psychotherapy And Psychosomatics Reporting Clinical Improvement In Chronic Insomnia Patients Using Nexalin's High-Power 15 mA, 77.5Hz Stimulation Approach

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

Nexalin To Begin Enrollment For Pivotal HALO Clarity Insomnia Trial In Q2 2026; Targeting FDA De Novo Pathway

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China

Nexalin Technology Advances FDA Alzheimer's Strategy After Meetings In The U.S. And China; Plans To Submit An Amended FDA Q-Submission Application Based On These Strategy Meetings In Q2 2026

Nexalin Technology Advances FDA Alzheimer's Strategy After Meetings In The U.S. And China; Plans To Submit An Amended FDA Q-Submission Application Based On These Strategy Meetings In Q2 2026

Nexalin Technology Advances FDA Alzheimer's Strategy After Meetings In The U.S. And China; Plans To Submit An Amended FDA Q-Submission Application Based On These Strategy Meetings In Q2 2026

Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

Exclusive-Nexalin Says Peer-Reviewed Study Reports Statistically Significant Reductions In Self-Injury Behaviors And Depression Symptoms In Female Adolescents

EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device

Nexalin Technology Q4 EPS $(0.13) Misses $(0.12) Estimate, Sales $171.895K Beat $80.000K Estimate

Nexalin Technology shares are trading higher after the company announced pivotal clinical trial of HALO Clarity for the treatment of insomnia to support planned de novo submission to the FDA.

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

EXCLUSIVE: Penny Stock Nexalin Advances Pivotal Trial Aiming To Tackle Severe Insomnia